SG11201805202VA - 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS - Google Patents
6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDSInfo
- Publication number
- SG11201805202VA SG11201805202VA SG11201805202VA SG11201805202VA SG11201805202VA SG 11201805202V A SG11201805202V A SG 11201805202VA SG 11201805202V A SG11201805202V A SG 11201805202VA SG 11201805202V A SG11201805202V A SG 11201805202VA SG 11201805202V A SG11201805202V A SG 11201805202VA
- Authority
- SG
- Singapore
- Prior art keywords
- massachusetts
- street
- international
- road
- rule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662279037P | 2016-01-15 | 2016-01-15 | |
| PCT/IB2017/050094 WO2017122116A1 (en) | 2016-01-15 | 2017-01-09 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805202VA true SG11201805202VA (en) | 2018-07-30 |
Family
ID=57838441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805202VA SG11201805202VA (en) | 2016-01-15 | 2017-01-09 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10590128B2 (ko) |
| EP (1) | EP3402796B1 (ko) |
| JP (1) | JP6929857B2 (ko) |
| KR (1) | KR102206321B1 (ko) |
| CN (1) | CN108884093B (ko) |
| AU (1) | AU2017208119B2 (ko) |
| BR (1) | BR112018013955B1 (ko) |
| CA (1) | CA3011201C (ko) |
| ES (1) | ES2837018T3 (ko) |
| IL (1) | IL260298B (ko) |
| MX (1) | MX2018008653A (ko) |
| RU (1) | RU2712455C1 (ko) |
| SG (1) | SG11201805202VA (ko) |
| TW (1) | TWI633104B (ko) |
| WO (1) | WO2017122116A1 (ko) |
| ZA (1) | ZA201803776B (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201805202VA (en) | 2016-01-15 | 2018-07-30 | Pfizer | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
| JP7015092B2 (ja) | 2016-07-28 | 2022-02-02 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物 |
| WO2019146739A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する縮環化合物 |
| CN108997287B (zh) * | 2018-07-23 | 2021-12-28 | 陕西师范大学 | 以四氟硼酸的离子液体为氟源催化合成4-氟代四氢吡喃衍生物的方法 |
| CN109608451A (zh) * | 2018-12-17 | 2019-04-12 | 上海药明康德新药开发有限公司 | 一种2-氧亚基-吡啶并[2,3-d]氮杂卓-7(2H)-甲酸叔丁酯合成方法 |
| WO2023172497A2 (en) * | 2022-03-07 | 2023-09-14 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or preventing cocaine use disorder |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2003068751A1 (en) | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders |
| WO2003068732A2 (en) | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds |
| JPWO2005023771A1 (ja) | 2003-09-05 | 2006-11-02 | 小野薬品工業株式会社 | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| US20050137186A1 (en) * | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| ES2375963T3 (es) | 2003-12-18 | 2012-03-07 | Abbott Gmbh & Co. Kg | Tetrahidrobenzacepinas y su uso en la modulación del receptor d3 de la dopamina. |
| GB0412314D0 (en) | 2004-06-02 | 2004-07-07 | Glaxo Group Ltd | Compounds |
| KR101389246B1 (ko) * | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| CA2603049A1 (en) | 2005-04-01 | 2006-10-05 | Warner-Lambert Company Llc | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia |
| CA2619450C (en) | 2005-09-01 | 2013-10-22 | Eli Lilly And Company | 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| WO2007140213A1 (en) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| CA2692440A1 (en) * | 2006-07-20 | 2008-01-24 | Cascade Therapeutics Inc. | Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
| GB0619176D0 (en) | 2006-09-29 | 2006-11-08 | Lectus Therapeutics Ltd | Ion channel modulators & uses thereof |
| WO2008051547A1 (en) | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| GB0710844D0 (en) | 2007-06-06 | 2007-07-18 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| US8386479B2 (en) | 2007-07-09 | 2013-02-26 | University Of Toronto | Routing methods for multiple geographical entities |
| CN101712675B (zh) | 2008-10-07 | 2013-07-03 | 江苏恒谊药业有限公司 | 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用 |
| NZ755378A (en) | 2009-03-18 | 2022-07-29 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| SG2014011555A (en) | 2011-08-15 | 2014-08-28 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
| TWI585082B (zh) | 2012-11-29 | 2017-06-01 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途 |
| WO2014106800A2 (en) | 2013-01-04 | 2014-07-10 | Aurigene Discovery Technologies Limited | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| FI3421462T3 (fi) * | 2013-06-27 | 2023-06-26 | Pfizer | Heteroaromaattisia yhdisteitä ja niiden käyttö dopamiini-d1-ligandeina |
| US20160159805A1 (en) | 2013-07-17 | 2016-06-09 | Bayer Cropscience Ag | Heterocyclic sulfonylamino(thio)carbonyl-derivatives with nematicidal properties |
| SG11201805202VA (en) | 2016-01-15 | 2018-07-30 | Pfizer | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
-
2017
- 2017-01-09 SG SG11201805202VA patent/SG11201805202VA/en unknown
- 2017-01-09 BR BR112018013955-6A patent/BR112018013955B1/pt active IP Right Grant
- 2017-01-09 CN CN201780017459.4A patent/CN108884093B/zh active Active
- 2017-01-09 ES ES17700748T patent/ES2837018T3/es active Active
- 2017-01-09 US US16/069,585 patent/US10590128B2/en active Active
- 2017-01-09 MX MX2018008653A patent/MX2018008653A/es unknown
- 2017-01-09 JP JP2018536264A patent/JP6929857B2/ja active Active
- 2017-01-09 EP EP17700748.1A patent/EP3402796B1/en active Active
- 2017-01-09 RU RU2018125942A patent/RU2712455C1/ru active
- 2017-01-09 AU AU2017208119A patent/AU2017208119B2/en active Active
- 2017-01-09 KR KR1020187023277A patent/KR102206321B1/ko active IP Right Grant
- 2017-01-09 WO PCT/IB2017/050094 patent/WO2017122116A1/en active Application Filing
- 2017-01-09 CA CA3011201A patent/CA3011201C/en active Active
- 2017-01-13 TW TW106101286A patent/TWI633104B/zh active
-
2018
- 2018-06-07 ZA ZA2018/03776A patent/ZA201803776B/en unknown
- 2018-06-27 IL IL260298A patent/IL260298B/en unknown
-
2020
- 2020-01-23 US US16/750,505 patent/US11390623B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190047997A1 (en) | 2019-02-14 |
| IL260298B (en) | 2021-07-29 |
| EP3402796A1 (en) | 2018-11-21 |
| CA3011201A1 (en) | 2017-07-20 |
| CA3011201C (en) | 2020-09-22 |
| AU2017208119A1 (en) | 2018-06-28 |
| KR20180100432A (ko) | 2018-09-10 |
| RU2712455C1 (ru) | 2020-01-29 |
| BR112018013955A2 (pt) | 2018-12-11 |
| BR112018013955B1 (pt) | 2024-01-16 |
| CN108884093A (zh) | 2018-11-23 |
| TWI633104B (zh) | 2018-08-21 |
| CN108884093B (zh) | 2021-07-09 |
| JP2019501930A (ja) | 2019-01-24 |
| MX2018008653A (es) | 2018-12-10 |
| WO2017122116A1 (en) | 2017-07-20 |
| US10590128B2 (en) | 2020-03-17 |
| ES2837018T3 (es) | 2021-06-29 |
| TW201736367A (zh) | 2017-10-16 |
| JP6929857B2 (ja) | 2021-09-01 |
| IL260298A (en) | 2018-08-30 |
| ZA201803776B (en) | 2020-09-30 |
| KR102206321B1 (ko) | 2021-01-21 |
| US11390623B2 (en) | 2022-07-19 |
| AU2017208119B2 (en) | 2019-11-07 |
| US20200157098A1 (en) | 2020-05-21 |
| EP3402796B1 (en) | 2020-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805202VA (en) | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201408044QA (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201909841RA (en) | Antitumoral compounds |